Past ASX announcements
2023 ASX Announcements
Notification regarding unquoted securities – IMC (12/07/2023)
Immuron Chairman Transition (30/06/2023)
Letter to Shareholders (22/06/2023)
Immuron CEO, Steven Lydeamore presents at LD Micro (07/06/2023)
Immuron Initiates Recruitment of Travelan Clinical Study (30/05/2023)
FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic (08/05/2023)
Immuron CEO Steven Lydeamore to present at Coffee Microcaps (02/05/2023)
Q3 FY23 Business Update Presentation (19/04/2023)
Q3 FY23 Business Update Webinar (11/04/2023)
Immuron Q3 Sales reach 150% of 1H Sales (06/04/2023)
Appendix 4D and Half Year Report FY2023 (28/02/2023)
Business Update Presentation (28/02/2023)
Immuron CEO Steven Lydeamore to host investor webinar (15/02/2023)
Immuron and US NMRC respond to CampETEC FDA Clinical Hold (25/01/2023)
US DOD Travelan Clinical Field Study Recruitment Milestone (18/01/2023)
Immuron Receives European Patent on Drug Composition (17/01/2023)
2022 ASX Announcements
Immuron Receives FDA Approval for Travelan IND Application (23/12/2022)
Immuron Submits IND Application To FDA for Travelan (05/12/2022)
Amended Constitution of Immuron Limited (01/12/2022)
Results of Annual General Meeting (21/11/2022)
Immuron AGM Presentation (21/11/2022)
Immuron completes strategic investment in Ateria Health (16/11/2022)
Immuron CEO Steven Lydeamore to present at AusBioInvest (26/10/2022)
Notice of Annual General Meeting/Proxy Form (21/10/2022)
Immuron investment in leading gut health biotech Ateria Health (13/10/2022)
Immuron Executes Travelan Clinical Trial Agreement Pharmaron (4/10/2022)
Appendix 4G – FY 30 June 2022 (09/09/2022)
FY22 Results and Business Update Presentation (31/08/2022)
Appendix 4E and Preliminary Final Report (31/08/2022)
Immuron CEO, Steven Lydeamore, to host an investor webinar (29/08/2022)
Immuron Update on IMM-124E SARS-CoV-2 Research (19/08/2022)
Update on IND Application for Campylobacter ETEC Therapeutic (26/07/2022)
North American Travelan Sales up 494%, Global sales up 431% (11/07/2022)
European Patent Notification on Drug Composition for CDI (07/07/2022)
Change of Director's Interest Notice – DP (04/07/2022)
Notification regarding unquoted securities - IMC (01/07/2022)
Change of Director's Notice (15/06/2022)
Notification of cessation of securities (14/06/2022)
Notification of cessation of securities (10/06/2022)
Change in substantial holding (25/05/2022)
US DoD NMRC files IND application with FDA (11/05/2022)
US DoD Uniformed Services University Clinical Update (09/05/2022)
Appointment of Mr Steven Lydeamore as Chief Executive Officer (05/05/2022)
Immuron Q3 Global Sales up 216% YoY (27/04/22)
Immuron new MTEC project proposal (19/04/22)
Initial Director’s Interest Notice (16/03/2022)
Appointment of Paul Brennan as Non-Executive Director (16/03/2022)
Half Yearly Report and Accounts (25/02/22)
Response to ASX query (24/01/22)
Changes in substantial holding (24/01/22)
Immuron receives $306,154 R&D Tax Concession Refund (17/01/22)
Immuron receives European patent on Drug to treat Diarrhoea (13/01/22)
Change in substantial holding (13/01/22)
Immuron awarded $6.2 million US DoD funding for Travelan (12/01/22)
Change in substantial holding (6/01/22)
2021 ASX Announcements
Application for quotation of securities - IMC (17/12/21)
Proposed issues of securites (16/12/21)
Investor Presentation (16/12/21)
Results of Annual General Meeting (15/12/21)
Change in substantial holding (1/12/21)
Notice of Annual General Meeting/ Proxy Form (16/11/21)
US DoD Travelan Clinical Update (15/11/21)
Jobkeeper Payment Notification (11/11/21)
US DoD Naval Medical Research Center Clinical Update (10/11/21)
Notification regarding unquoted securities - IMC (5/11/21)
Application for quotation of securities - IMC (5/11/21)
Immuron filed XBRL data with the SEC (3/11/21)
Form 20-F filed with the SEC (29/10/21)
Amended Appendix 3H (27/10/21)
Notification of cessation of securities - IMC (26/10/21)
Change in substantial holding (20/10/21)
Change in substantial holding (15/10/21)
IMM124E Demonstrates Antiviral T-Cell Immunity (8/10/21)
Corporate Governance Statement (30/09/21)
Annual Report to Shareholders (30/09/21)
Director Resignation - Peter Anastasiou (24/09/21)
Reinstatement to Official Quotation (23/9/21)
Immuron Planned Acquisition of R&D Vaccine Company (23/9/21)
Preliminary Final Report (31/08/21)
Change in Substantial Holding (3/06/21)
Suspension from Official Quotation (31/05/21)
Change in Substantial Holding (20/05/21)
IMM124E May Offer New Modality for Inhibition of SARS-CoV-2 (13/05/21)
Half Yearly Reports and Accounts (25/02/21)
Change of Director's Notice (9/02/21)
2020 ASX Announcements
Immuron Sars-CoV-2 Research Agreement with Monash University (15/12/20)
Change of Director's Notice (26/11/20)
Immuron receives AUD $358,280 R&D tax concession refund (24/11/20)
Change of Director's Interest Notivce (x5) (17/11/20)
Change in substantial holding (16/11/20)
Proposed Issue of Securities (13/11/20)
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine (9/11/20)
2020 AGM Presentation (29/10/20)
Immuron filed XBRL data with the SEC (29/10/20)
Form 20-F filed with the SEC (29/10/20)
Change in substantial holding (19/10/20)
Immuron Travelers' Diarrhea market update (13/10/20)
Time of AGM clarification (30/09/20)
Corporate Governance Statement (25/09/20)
Notice of Annual General Meeting/Proxy Form (25/09/20)
Annual Report to shareholders (25/09/20)
Change in substantial holding (16/09/20)
Change in substantial holding (04/09/20)
Appendix 4E and 2020 Financial Report (01/09/20)
Change in substantial holding (28/08/20)
Change of Director's Interest Notice (PA&SA) (21/08/20)
Change in substantial holding (21/08/20)
Change in substantial holding (19/08/20)
Change in substantial holding (12/08/20)
Change in substantial holding (05/08/20)
Change in substantial holding (31/07/20)
Appendix 2A and 708A Notice (29/07/20)
Proposed issue of Securities – IMC (29/07/20)
Change in substantial holding (28/07/20)
Proposed issue of Securities - IMC (27/07/20)
US SEC Form 6-K Filing (24/07/20)
Prospectus Supplement (24/07/20)
Appendix 2A and 708A Notice (24/07/20)
Closing of US$20 Million Registered Direct Offering (24/07/20)
Proposed issue of Securities – IMC (23/07/20)
Immuron Announces US$20.0 Million Registered Direct Offering (22/07/20)
Immuron Reports Neutralizing activity Against SARS-CoV-2 (21/07/20)
US DoD Receives FDA Guidance on clinical development plans (20/07/20)
Appendix 2A and 708A notice (03/07/20)
Proposed issue of Securities – IMC (01/07/20)
Change in substantial holding (26/06/20)
Change in substantial holding (25/06/20)
Change of Director's Interest Notice (RA) (23/06/20)
Change of Director's Interest Notice (DP) (23/06/20)
Appendix 2A and 708A notice (23/06/20)
Change in substantial holding (23/06/20)
Proposed issue of Securities – IMC (22/06/20)
Proposed issue of Securities – IMC (22/06/20)
Change in substantial holding (22/06/20)
IMC & CSIRO to produce oral therapeutic for DoD evaluation (19/06/20)
Change in substantial holding (GL) (19/06/20)
Change of Director's Interest Notice PA (19/06/20)
Change in substantial holding (19/06/20)
Change in substantial holding (18/06/20)
Change in substantial holding (17/06/20)
Appendix 2A and 708A notice (16/06/20)
Ceasing to be a substantial holder (16/06/20)
Change in substantial holding (16/06/20)
Proposed issue of Securities – IMC (15/06/20)
Change of Director's Interest Notice (DP) (12/06/20)
Response to ASX Price Query (10/06/20)
US Defense requests FDA meeting (09/06/20)
Immuron Board Relinquish Cash Payment of Fees (27/04/20)
Immuron Global Sales Up 60% (20/04/20)
Final Director's Interest Notice (GJ) (26/03/20)
Resignation of Managing Director and cuts amid Covid19 (25/03/20)
Immuron Provides Update on First Half of FY20 Results (02/03/20)
Half Yearly Report and Accounts (26/02/20)
Change in substantial holding (12/02/20)
North American Travelan sales up 98% to Dec 2019 (28/01/20)
Change of Share Registry (20/01/20)
Immuron CEO to present at Biotech Conference in SFO (08/01/20)
